Vitamin D deficiency is associated with prostate tumor gene expression
“I think the one thing that we're hopeful for is that people will start to look at vitamin D as a potential chemoprevention agent,” says Adam B. Murphy, MD, MBA, MSCI.
Dr. Laviana on novel opioid minimization protocol after urologic robotic surgery
"We wanted to implement an opioid minimization pathway that was easy to follow and successful,” says Aaron Laviana, MD.
Dr. Nguyen on study of PSMA-targeting fluorescent dye for image-guided prostatectomy
The study showed that the PSMA-targeting fluorophore IS-002 enabled enhanced intraoperative tumor detection during robotic prostatectomy.
Sabizabulin active in metastatic castration-resistant prostate cancer
The utilization of sabizabulin in patients yielded significant and durable objective tumor responses, according to results of a phase 1b/2 trial (NCT03752099) presented at the 2022 AUA Annual Meeting.
Novel PSMA-targeting fluorescent dye facilitates image-guided robotic prostatectomy
IS-002, an investigational, near-infrared, PSMA-targeting fluorophore, enhanced intraoperative cancer visualization during robotic prostatectomy.
ARASENS darolutamide safety update shows no increased toxicity in men with mHSPC
Adding darolutamide to androgen deprivation therapy and docetaxel did not increase the incidence or severity of adverse events in patients with metastatic hormone-sensitive prostate cancer.
New analysis supports PSA screening for Black men
The study data strongly support PSA screening, particularly in Black men, for whom there is a paucity of clinical trial evidence, according to lead author Spyridon Basourakos, MD.
Dr. Fleming on imaging agent 18F-rhPSMA-7.3 and SPOTLIGHT trial in prostate cancer
In the phase 3 SPOTLIGHT trial, PET imaging with 18F-rhPSMA-7.3 frequently led to post-scan disease upstaging compared with baseline conventional imaging in men with prostate cancer recurrence.
Dr. Rafael Sanchez-Salas on the ideal patient for focal therapy for prostate cancer
“Focal therapy represents a middle ground between active surveillance and more radical options,” says Rafael Sanchez-Salas, MD.
Long-term darolutamide data show sustained efficacy in nmCRPC
The benefit with darolutamide was observed, regardless of whether or not patients had prior local therapy.
Dr. Eastham describes updates to AUA guideline for clinically localized prostate cancer
The AUA partnered with ASTRO on the guideline and it was endorsed by the SUO.
Enzalutamide/ADT survival benefit in mHSPC unaffected by prior local therapy
The findings came from a post-hoc analysis of the phase 3 ARCHES trial.
Acceptable toxicity profile is seen with relugolix in advanced prostate cancer
“Relugolix, an oral nonpeptide GnRH receptor antagonist, was generally well tolerated in the phase 3 HERO study,” wrote Bryan Mehlhaff, MD, and coauthors.
Niraparib/abiraterone regimen shows early efficacy signals in metastatic prostate cancer
A regimen combining the PARP inhibitor and the androgen receptor pathway inhibitor plus prednisone showed promise in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations who had progressed on prior treatment with an androgen receptor–targeted therapy.
Darolutamide is well tolerated in patients with mCRPC over long term
No grade 3 TEAEs were reported in more than 1 patient at a time, and investigators deemed these grade 3 TEAEs to be unrelated to darolutamide treatment.
Dr Adam Murphy on vitamin D deficiency and prostate cancer in Black men
“I had long thought that vitamin D deficiency could be a risk factor for prostate cancer,” says Adam B. Murphy, MD, MBA, MSCI.
Novel PET imaging agent 18F-rhPSMA-7.3 increases upstaging in recurrent prostate cancer
Compared with baseline conventional imaging, PET imaging with 18F-rhPSMA-7.3 frequently led to post-scan disease upstaging in men with prostate cancer recurrence, according to the latest data from the phase 3 SPOTLIGHT trial.
Understanding patterns in prostate genomic testing using SEER and GPS assay
In a recent study presented at the 2021 AUA Annual Meeting, Scarlett Gomez, MPH, PhD, and co-authors investigated the determinants of selecting active surveillance/watchful waiting as a treatment path for patients with localized, low-risk prostate cancer.
Phase 2b data point to safety, efficacy of focal therapy in intermediate-risk prostate cancer
In a study presented at the 2021 AUA annual meeting, Behfar Ehdaie, MD, MPH, and colleagues assessed the efficacy of focal therapy in treating patients with grade group 2 or 3 prostate cancers.
Benefits of perioperative yoga for patients with prostate cancer
Dharam Kaushik, MD, and a team of investigators are the first to examine the benefits of perioperative yoga in patients diagnosed with localized prostate cancer.
Noninvasive miR Sentinel PCC4 Test accurately identifies prostate cancer
In a recent study presented at the 2021 AUA Annual Meeting, Laurence Klotz, MD, FRCSC, and a team of investigators determined the accuracy of the new miR Sentinel PCC4 Test, a urinalysis of low- to high-grade prostate cancer in men.
Dr. Klotz weighs in on the future of prostate cancer testing
In this video, Laurence Klotz, MD, FRCSC, discusses the miR Sentinel PCC4 Test and how it could change the future of prostate cancer testing.
Dr. Kaushik discusses the benefits of yoga for patients with prostate cancer
“Our data shows that in newly diagnosed men with prostate cancer, yoga improved quality of life [as well as] some immune markers, and [lowered] inflammation,” says Dharam Kaushik, MD.
Dr. Gao on treating re-emerged PARPi-resistant prostate cancer
“Some potential…combination therapy may be valuable, such as combining with a checkpoint inhibitor or some target senescence because this resistance involves those kinds of mechanisms,” says Allen C. Gao, MD, PhD.
Dr. Pavic on masitinib plus docetaxel in first-line mCRPC
“What we found was the [progression-free survival] value was improved in the subgroup of patients with low [alkaline phosphatase levels],” says Michel Pavic, MD.
Dr. Klotz discusses accuracy of miR Sentinel PCC4 Test for prostate cancer
“We think given the accuracy that this is potentially a game changer,” says Laurence Klotz, MD, FRCSC.
Dr. Shore on the benefits of starting darolutamide for patients with nmCRPC
“The take-home message for all practicing urologists should be that if you have an nmCRPC patient, don't wait for them to develop mCRPC based on conventional imaging…We have 3 really efficacious level 1 evidence studies that have demonstrated the value for starting any of these 3 drugs,” says Neal D. Shore, MD.
Dr. Gao on study of resistance to PARP inhibitor olaparib in prostate cancer
“In those resistance cells, there is a lot of senescence occurring there, so that provides some potential target…which can be used to improve those PARP inhibitor therapies,” says Allen C. Gao, MD, PhD.
Benefits of collecting and reporting smoking status in patients with GU cancer
"In the clinic, I think the biggest benefit, at least immediately, is that by asking and trying to figure out what a patient's tobacco use history is, you can help with quitting,” says Richard Matulewicz, MD, MS.
Study finds focal therapy a safe option for treating intermediate-risk prostate cancer
“Although [whole-gland] treatments are very successful, from the oncologic perspective, our goal was to develop and test a new treatment modality in which we treat only the area with the significant cancer using focused ultrasound in the MRI gantry,” says Behfar Ehdaie, MD, MPH.
2 Clarke Drive Cranbury, NJ 08512